IP Library Patent Application 11395121
Patent Application
App. No. 11/395,121

Neisseria meningitidis antigens and compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/395,121
Abstract

This invention provides, among other things, protein, polypeptides, and fragments thereof, derived from bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto (e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments and/or nucleic acids.

Claims (18)

1 . An isolated, immunogenic polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) an amino acid sequence having 90% or greater sequence identity to SEQ ID NO:34;

(b) an amino acid sequence having 90% or greater sequence identity to SEQ ID NO:18;

(c) an amino acid sequence having 90% or greater sequence identity to SEQ ID NO:20; and

(d) an amino acid sequence having 90% or greater sequence identity to SEQ ID NO:16.

2 . The isolated, immunogenic polypeptide of claim 1 wherein the amino acid sequence has 95% or greater sequence identity to SEQ ID NO: 33.

3 . The isolated, immunogenic polypeptide of claim 1 wherein the amino acid sequence has 99% or greater sequence identity to SEQ ID NO: 33.

4 . The isolated, immunogenic polypeptide of claim 1 wherein the amino acid sequence comprises SEQ ID NO: 33.

5 . The isolated, immunogenic polypeptide of claim 1 wherein the amino acid sequence has 95% or greater sequence identity to SEQ ID NO: 18.

6 . The isolated, immunogenic polypeptide of claim 1 wherein the amino acid sequence has 99% or greater sequence identity to SEQ ID NO:18.

7 . The isolated, immunogenic polypeptide of claim 1 wherein the amino acid sequence comprises SEQ ID NO:18.

8 . An antibody which binds to the immunogenic polypeptide of claim 1 .

9 . A nucleic acid molecule comprising a protein coding sequence which encodes the immunogenic polypeptide of claim 1 .

10 . A vaccine comprising the immunogenic polypeptide of claim 1 .

11 . The vaccine of claim 10 further comprising a pharmaceutically effective carrier.

12 . The vaccine of claim 11 further comprising an adjuvant.

13 . A diagnostic kit comprising the immunogenic polypeptide of claim 1 or the antibody of claim 8 .

14 . A prophylactic or therapeutic method comprising administering a therapeutically effective amount of the vaccine of claim 10 to a subject.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2013
From: GALEOTTI, CESIRA; GRANDI, GUIDO; MASIGNANI, VEGA; MORA, MARIROSA; RATTI, GIULIO (DECEASED), RATTI, LEHUTA FOR; RAPPUOLI, RINO; SCARLATO, VINCENZO; SCARSELLI, MARIA; PIZZA, MARIAGRAZIA
To: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Reel/Frame 030672/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2013
From: FRASER-LIGGETT, CLAIRE; HICKEY, ERIN; PETERSON, JEREMY; TETTELIN, HERVE; VENTER, J. CRAIG
To: J. CRAIG VENTER INSTITUTE, INC.
Reel/Frame 030672/0207 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2013
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 030672/0264 →